Medical Device News Magazine

Stryker’s Triathlon Tritanium Baseplate Marks a Decade of Positive Patient Impact

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Stryker (NYSE: SYK), one of the world’s leading medical technology companies, continues its year of milestones celebration with the 10th anniversary of the Triathlon Tritanium baseplate. Since its introduction in 2013, Triathlon Cementless, which includes the Triathlon Tritanium Baseplate, has delivered a decade of positive patient impact, demonstrated impressive survivorship data and has become a trusted solution for surgeons across the globe.

With over 1 million knees implanted to date1, Stryker’s Triathlon Cementless combines the kinematics of Triathlon with a proprietary design and highly porous biologic fixation technology. With its unique ability to enhance bone integration, Triathlon Cementless has provided patients with higher satisfaction2,3 and lower revision rates4 compared to cemented knees. Triathlon Cementless provides fixation and results that surgeons can trust,1-7 supported by over 10 years of clinical use and 99% survivorship at five years.4

Stryker has been setting the standard and leading the industry with cementless knee procedures for a decade,” said Lisa Kloes, vice president and general manager, of Stryker’s Knees business. “We are seeing a growing trend in the adoption of Triathlon Cementless and expect those numbers to continue to increase, especially as impressive survivorship data continues to roll in. I’m thrilled to celebrate this milestone of patient impact as we continue our mission to make healthcare better.”

Marking its 10th anniversary, the Triathlon Tritanium baseplate is designed with Stryker Orthopaedic Modeling and Analytics (SOMA) and enabled by Stryker’s proprietary additive manufacturing technology. Providing a highly porous metal biologic fixation, this baseplate offers patients higher satisfaction3 and hospitals improved efficiency.2.5

As the volume of total knee arthroplasty (TKA) procedures continues to increase, the costs associated with this surgical procedure continues to be an important topic. Triathlon Cementless allows for reduction of operating room time by 10-15 minutes compared to cemented knees2,5 and the elimination of the cost and storage of bone cement and cement accessories.6

“As a leader in additive manufacturing technologies, Stryker has differentiated itself from the competition when it comes to specialized medical devices, particularly with cementless fixation,” said Kloes. “Our commitment to pushing technological boundaries in orthopaedic implant innovation sets us apart and allows us to provide best-in-class options for our customers and their patients.”

Those living with joint pain are encouraged to speak with their healthcare professional about available treatment plans. As a provider, surgeons can help patients get educated on options that may help prevent further pain and complications. To learn more about joint health treatment options for patients, please visit patients.stryker.com.

All surgery carries risk. Surgeons must rely on their own professional clinical judgment when deciding whether to utilize a particular technology when treating a patient in their own practice. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any technology before using it in surgery. Not all patients will have the same postoperative recovery and activity level. Individual results vary.

References :

  1. Stryker’s sales data on file
  2. Sharpe, K., Robinson, K., Cohen, R., Barnett TM., Rastogi, A., Masini, M. Does Implant Fixation Affect Early Return to Function Following Primary Total Knee Arthroplasty. ISTA 2018. London, UK.
  3. Hannon CP, Salih R, Barrack RL, Nunley RM. Cementless Versus Cemented Total Knee Arthroplasty: Concise Midterm Results of a Prospective Randomized Controlled Trial. JBJS. 2023 Jun 22:10-2106.
  4. Nam D, Bhowmik-Stoker M, Mahoney OM, Dunbar MJ, Barrack RL. Mid-Term Performance of the First Mass-Produced Three-Dimensional Printed Cementless Tibia in the United States as Reported in the American Joint Replacement Registry. J Arthroplasty. 2023 Jan;38(1):85-89.
  5. Nam, D, et al. Cemented Versus Cementless Total Knee Arthroplasty of the Same Modern Design: A Prospective, Randomized Trial. The Journal of Bone and Joint Surgery 101(13):p 1185-1192, July 3, 2019. | DOI: 10.2106/JBJS.18.01162
  6. Lawrie CM, Schwabe M, Pierce A, Nunley RM, Barrack RL. The cost of implanting a cemented versus cementless total knee arthroplasty. Bone Joint J. 2019 Jul;101-B(7_Supple_C):61-63. doi: 10.1302/0301-620X.101B7.BJJ-2018-1470.R1. PMID: 31256655.
  7. Triathlon Surgical Compendium TRIATH-SP-30_Rev-2_34473
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”